Achieve Life Sciences Inc., of Bothell, Wash., said the FDA accepted its IND application for cytisine, a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Achieve plans to start a phase III trial in the U.S. testing cytisine as a smoking cessation treatment in the first half of 2018.